SMAD4 and non-small cell lung carcinoma: The expression of Smad4 in NSCLC tissues with clinical stage IIIA (17.4%; 4/23) was lower than that in NSCLC tissues with clinical stage IB–IIB (72.4%; 21/29) (P < 0.001) (Table 6; Fig. 6d).